Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.

Gentilini LD, Jaworski FM, Tiraboschi C, Pérez IG, Kotler ML, Chauchereau A, Laderach DJ, Compagno D.

Oncotarget. 2017 Jul 4;8(27):44654-44668. doi: 10.18632/oncotarget.17963.

2.

In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development.

Jaworski FM, Gentilini LD, Gueron G, Meiss RP, Ortiz EG, Berguer PM, Ahmed A, Navone N, Rabinovich GA, Compagno D, Laderach DJ, Vazquez ES.

Clin Cancer Res. 2017 Sep 1;23(17):5135-5148. doi: 10.1158/1078-0432.CCR-17-0112. Epub 2017 May 16.

3.

Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells.

Bacigalupo ML, Manzi M, Espelt MV, Gentilini LD, Compagno D, Laderach DJ, Wolfenstein-Todel C, Rabinovich GA, Troncoso MF.

J Cell Physiol. 2015 Jun;230(6):1298-309. doi: 10.1002/jcp.24865.

PMID:
25469885
4.

Regulation of galectins by hypoxia and their relevance in angiogenesis: strategies and methods.

Salatino M, Croci DO, Laderach DJ, Compagno D, Gentilini L, Dalotto-Moreno T, Dergan-Dylon LS, Méndez-Huergo SP, Toscano MA, Cerliani JP, Rabinovich GA.

Methods Mol Biol. 2015;1207:293-304. doi: 10.1007/978-1-4939-1396-1_19.

PMID:
25253148
5.

Study of galectins in tumor immunity: strategies and methods.

Cerliani JP, Dalotto-Moreno T, Compagno D, Dergan-Dylon LS, Laderach DJ, Gentilini L, Croci DO, Méndez-Huergo SP, Toscano MA, Salatino M, Rabinovich GA.

Methods Mol Biol. 2015;1207:249-68. doi: 10.1007/978-1-4939-1396-1_16.

PMID:
25253145
6.

Glycans and galectins in prostate cancer biology, angiogenesis and metastasis.

Compagno D, Gentilini LD, Jaworski FM, Pérez IG, Contrufo G, Laderach DJ.

Glycobiology. 2014 Oct;24(10):899-906. doi: 10.1093/glycob/cwu055. Epub 2014 Jun 16.

PMID:
24939371
7.

Galectins: major signaling modulators inside and outside the cell.

Compagno D, Jaworski FM, Gentilini L, Contrufo G, González Pérez I, Elola MT, Pregi N, Rabinovich GA, Laderach DJ.

Curr Mol Med. 2014;14(5):630-51. Review.

PMID:
24894174
8.

Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.

Laderach DJ, Gentilini L, Jaworski FM, Compagno D.

Prostate Cancer. 2013;2013:519436. doi: 10.1155/2013/519436. Epub 2013 Sep 24. Review.

9.

Delineating the "galectin signature" of the tumor microenvironment.

Compagno D, Laderach DJ, Gentilini L, Jaworski FM, Rabinovich GA.

Oncoimmunology. 2013 Apr 1;2(4):e23565.

10.

A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.

Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.

Cancer Res. 2013 Jan 1;73(1):86-96. doi: 10.1158/0008-5472.CAN-12-1260. Epub 2012 Oct 29.

11.

TSLP1: a new piece in the puzzle of tumor-associated Th2-type inflammation.

Laderach DJ, Pesoa SA, Compagno D, Rabinovich GA.

Immunotherapy. 2011 Jun;3(6):713-7. doi: 10.2217/imt.11.67. No abstract available.

PMID:
21668306
12.

Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings.

Laderach DJ, Compagno D, Toscano MA, Croci DO, Dergan-Dylon S, Salatino M, Rabinovich GA.

IUBMB Life. 2010 Jan;62(1):1-13. doi: 10.1002/iub.281. Review.

Supplemental Content

Loading ...
Support Center